Mori Masahiro, Kuwabara Satoshi, Fukutake Toshio, Hattori Takamichi
Department of Neurology, Graduate School of Medicine, Chiba University, Inohana, Chuo-ku, Chiba, Japan.
Neurology. 2007 Apr 3;68(14):1144-6. doi: 10.1212/01.wnl.0000258673.31824.61.
We analyzed clinical recovery of 92 patients with Miller Fisher syndrome who had been treated with IV immunoglobulin (IVIg; n = 28), plasmapheresis (n = 23), and no immune treatment (n = 41). IVIg slightly hastened the amelioration of ophthalmoplegia and ataxia, but the times of the disappearances of those symptoms were similar among three groups. In Miller Fisher syndrome, IVIg and plasmapheresis seem not to have influenced patients' outcomes, presumably because of good natural recovery.
我们分析了92例接受静脉注射免疫球蛋白（IVIg；n = 28）、血浆置换（n = 23）和未接受免疫治疗（n = 41）的米勒-费雪综合征患者的临床恢复情况。IVIg略微加速了眼肌麻痹和共济失调的改善，但三组患者这些症状消失的时间相似。在米勒-费雪综合征中，IVIg和血浆置换似乎并未影响患者的预后，可能是因为其自然恢复情况良好。
